Case ID: 94-075
Web Published: Dec 15, 2011
Available for: Licensing
We have developed a gene therapy for Haemophilia A that utilises a novel promoter and a highly-expressed sequence for the clotting protein Factor VIII.
Building on our expertise in Haemophili B treatment with a Factor IX gene therapeutic, we are currently in pre-clinical development of our FVIII medicament. Planning is underway to take this technology into the clinc.
Haemophilia A is caused by a defiency of the clotting factor “Factor VIII”. This is the most frequent clotting disorder, and has an incidence of approximately 1 in 5,000-10,000 male births. The direct (clotting factor therapeutics) and indirect (in-patient treatment) costs of treating Heamophilia A are substantial.
Please contact Chris Loryman, UCL Business PLC. T +44 (0)20 7679 9000 E email@example.com